Eyenovia
  • Home
  • About
    • About Eyenovia
    • Vision
    • Leadership
  • Technology
  • Pipeline
    • Eyenovia Pipeline
    • MydCombi (Mydriasis)
    • MicroLine (Presbyopia)
    • MicroPine (Myopia)
  • Partners
  • Investors
  • Careers
  • News + Resources
    • News
    • Resource Library
  • Menu Menu

Review of the impact of presbyopia on quality of life in the developing and developed world

Presbyopia and Near-Vision Impairement in Rural Northern China

Pharmacological treatments of presbyopia–a review of modern perspectives

Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia

Associations of presbyopia with vision-targeted health-related quality of life

Recent Posts

  • Eyenovia’s Presentation at the Ladenburg Thalmann Healthcare Conference Wednesday July 14, 2021 July 14, 2021
  • Eyenovia highlights Recent Progress in Three Phase 3 Programs, NDA Review Progress and Licensing Agreements Totaling up to $100 Million in Potential Pre-Commercial Revenue June 15, 2021
  • Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia May 25, 2021

Pipeline and Technology

  • MydCombi (Mydriasis)
  • MicroLine (Presbyopia)
  • MicroPine (Myopia)
  • Technology

Corporate Address

Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenoviabio.com

Copyright © 2021 Eyenovia, Inc. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
  • Contact
  • Safe Harbor
  • Privacy Policy
  • Terms of Use
Scroll to top